Illumina Ventures

Founding Partner Nick Naclerio leads the investment team and chairs the independent investment committee. Naclerio previously spent 12 years as Senior Vice President of Corporate Development at Illumina, where he led over 25 acquisitions, including the Solexa deal that delivered the core sequencing technology behind Illumina's market dominance.

It is an independent venture firm with its own fiduciary structure and investment committee. While Illumina provided the initial $100 million anchor commitment for the first fund, the firm has since raised outside capital from institutional LPs and makes investment decisions independently of Illumina's commercial interests.

Illumina Inc. serves as the anchor limited partner but does not control investment decisions. Illumina Ventures maintains an independent governance model that allows it to invest in companies that may compete with Illumina in specific product categories, which distinguishes it from traditional corporate venture arms.

The firm targets early-stage companies, typically from seed through Series B. Initial check sizes range from approximately $2 million to $10 million, with significant reserves held for follow-on rounds as portfolio companies progress toward clinical validation or commercial launch.

The firm has not publicly stated explicit sector exclusions. However, its publicly disclosed portfolio concentrates on genomics, diagnostics, life science tools, and digital health, with no known investments in therapeutics outside of genomics-enabled modalities or in traditional biopharma platforms.